MD Anderson announces new leadership structure
The University of Texas MD Anderson Cancer Center today announced a new leadership structure designed to enhance teamwork and collaborative decision-making. It is effective today.
The new structure is based on advancing institutional priorities of financial sustainability, connecting the MD Anderson community to its decision-making process and improved teamwork. Outcomes will include improved clarity in decision-making, increased...
Study shows biomarkers can predict which ER-positive breast cancer patients respond best to first-line therapy
Two challenges in treating patients with estrogen-positive breast cancer (ER+) have been an inability to predict who will respond to standard...
MD Anderson UTHealth Graduate School receives $10.5 million gift
Just as he has changed the lives of people suffering from a devastating genetic disease, molecular endocrinologist John J. Kopchick, Ph.D....
Making Cancer History® Seminar returns to Aspen
The University of Texas MD Anderson Cancer Center plans its 19th annual Making Cancer History® seminar in Aspen, free and open to the public July 24 at Aspen Meadows Resort’s Paepcke Auditorium, 1000 N. Third St.
The seminar will highlight advances in MD Anderson’s mission to end cancer, such as the use of immunotherapy in the fight against melanoma, which is a focus of the institution’s Moon Shots Program™, a comprehensive effort...
MD Anderson and Convergent R.N.R. Ltd. establish alliance to further develop new radiation technology with potentially fewer side effects
The University of Texas MD Anderson Cancer Center and Convergent R.N.R. Ltd. (CRnR) today announced a collaboration to further develop new...
Innovative therapy strategy for pancreatic cancer uses engineered exosomes targeting mutated KRAS gene
Genetic manipulation of exosomes, virus-sized particles released by all cells, may offer a new therapeutic approach to treating pancreatic...
MD Anderson and Hitachi to collaborate in research for treatment of oropharyngeal cancer of the head and neck
The University of Texas MD Anderson Cancer Center and Hitachi Healthcare Americas Corporation, have today announced that they have entered...
Higher gut bacteria diversity tied to slower metastatic melanoma progression
The blend of bacteria in the digestive tract of metastatic melanoma patients is associated with disease progression or delay in patients treated...
Two combination therapies shrink melanoma brain metastases in more than half of patients
High response rates to a pair of combination therapies point to potentially new options for a group of metastatic melanoma patients who have...
Combination therapy targets genetic mutation found in many cancers
A study at The University of Texas MD Anderson Cancer Center has shown promise for effective treatment of therapy-resistant cancers caused...